Correvio Pharma Corp. announced Mark H.N. Corrigan, MD, a current member of the company's Board of Directors, has been named Correvio's next Chief Executive Officer, effective March 14, 2019. William Hunter, MD, after a successful 6-year tenure as President and Chief Executive Officer, will transition out of his current role by the end of the first quarter of 2019.

Dr. Hunter will remain a member of the Company's Board of Directors. In addition to the CEO succession plan, Justin Renz, Chief Financial Officer of Correvio, assumed the responsibilities of President and Vanda De Cian, MD, joined the Board of Directors. Dr. De Cian will serve as a member of the Nominating, Governance and Compensation Committees.